Clinical Trials Logo

Medication Overuse Headache clinical trials

View clinical trials related to Medication Overuse Headache.

Filter by:

NCT ID: NCT05720819 Completed - Virtual Reality Clinical Trials

Biofeedback-VR for Treatment of Chronic Migraine

Start date: September 9, 2020
Phase: N/A
Study type: Interventional

Migraine is a common, debilitating neurologic condition affecting more than 900 million individuals worldwide. Established treatments for migraine include medications, vitamin and herbal supplements, neuromodulation, and behavioral treatment strategies. This study aims to determine whether a novel, home-based behavioral approach, combined biofeedback-virtual reality therapy, can improve self-reported migraine-related outcomes in individuals living with chronic migraine. In this randomized, controlled pilot study, 50 adults with chronic migraine are randomized to the experimental group (frequent use of a heart rate variability biofeedback-virtual reality device plus standard medical care; n=25) or wait-list control group (standard medical care alone; n=25). The primary outcome is reduction in mean monthly headache days between groups at 12 weeks. Secondary outcomes include mean change in acute analgesic use frequency, depression, migraine-related disability, stress, insomnia, and catastrophizing between groups at 12 weeks. Tertiary outcomes include change in heart rate variability and device-related user experience measures.

NCT ID: NCT05608642 Active, not recruiting - Clinical trials for Medication Overuse Headache

Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment

Start date: October 22, 2022
Phase: N/A
Study type: Interventional

Medication overuse headache is the chronicity of headaches, which occurs more than 15 days a month, as a result of frequent use of painkillers, opioids or migraine attack drugs (ergotamine, triptan) in individuals with pre-existing primary headache disease. In the treatment of this headache, two ways can be followed as slow drug discontinuation or sudden drug discontinuation. The most commonly used method is the sudden discontinuation of the overused analgesic agent, the initiation of prophylactic treatment, and then the application of bridge therapy for 6-10 days. Intravenous hydration, steroids, antiemetics, neuroleptic drugs and local anesthetic drugs such as lidocaine can be used in bridge treatment.

NCT ID: NCT05528081 Recruiting - Migraine Disorders Clinical Trials

Longitudinal Study of the Patients With Medication-overuse Headache or Migraine That Completed Baseline MRI

LMMM
Start date: October 1, 2022
Phase:
Study type: Observational

This is a phone interview research study for patients with migraine or medication-overuse headache (MOH) who have completed baseline MRI scans. Participants will be interviewed by phone at 3, 12, 24 months after the baseline MRI scans. The purpose of this study is to potentially identify the baseline brain functional or structural signatures (functional connectivity, regional homogeneity, amplitude of low frequency fluctuation, and so such) that are predictive of the short- and long- term outcomes as well as treatment response of migraine and MOH patients.

NCT ID: NCT05452239 Recruiting - Migraine Clinical Trials

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Start date: July 1, 2022
Phase: Phase 4
Study type: Interventional

Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications. Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.

NCT ID: NCT05334927 Not yet recruiting - Migraine Clinical Trials

China HeadAche DIsorders RegiStry

CHAIRS
Start date: August 29, 2022
Phase:
Study type: Observational [Patient Registry]

It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS), patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.

NCT ID: NCT04772742 Completed - Migraine Clinical Trials

Eptinezumab in Adults With Migraine and Medication Overuse Headache

Sunlight
Start date: February 17, 2021
Phase: Phase 3
Study type: Interventional

This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache

NCT ID: NCT04336267 Completed - Chronic Migraine Clinical Trials

Anodal tDCS in Chronic Migraine With Medication Overuse

Start date: January 15, 2015
Phase: N/A
Study type: Interventional

Non-invasive neuromodulation has been applied in several forms of primary headaches, and its usefulness has been suggested for both episodic and chronic migraine (CM). Transcranial direct current stimulation (tDCS) represents a non-invasive electrical stimulation technique that modulates neural brain activity by means of low amplitude direct current trough surface electrodes. Very little evidence is available on the potential effect of tDCS in medication overuse and in the management of medication overuse headache (MOH), a condition frequently associated to CM. CM associated to MOH still represents a challenge for physicians and patients due to the high prevalence in the general population, the associated severe disability, and the high costs imposed by the treatment. The aim of the study was to investigate the possible application of tDCS in the management of CM associated to MOH. The primary objective of this pilot study was therefore to investigate the efficacy of anodal tDCS delivered on the primary motor cortex (M1) as add-on therapy to an in-hospital detoxification protocol in subjects affected by CM and MOH. The secondary objective was to evaluate the possible changes induced by tDCS on conventional EEG in order to obtain further clues about the effects of tDCS on brain activity.

NCT ID: NCT04228809 Completed - Migraine Disorders Clinical Trials

tDCS in Chronic Migraine With Medication Overuse (Edisom)

Edisom
Start date: December 1, 2015
Phase: N/A
Study type: Interventional

Transcranial direct current stimulation (tDCS) was suggested to provide beneficial effects in chronic migraine (CM), a condition often associated with medication overuse (MO) for which no long-term therapy is available.

NCT ID: NCT04090333 Completed - Migraine Clinical Trials

Endocrinological Profile in Patients With Medication-overuse Headache Before and After Withdrawal Therapy

ENDOMOH
Start date: August 1, 2019
Phase:
Study type: Observational

The project will be conducted to investigate the hormonal homeostasis in men and women, with a special emphasis on sex hormones in men and AMH level in women, before and after withdrawal of the overused analgesics among MOH patients. Additionally, a more broad endocrine profile will be explored before and after withdrawal. It is hypothesized that patients with MOH have disturbed hormone levels, which is normalized after withdrawal of the medication-overuse.

NCT ID: NCT03767062 Completed - Clinical trials for Chronic Migraine, Headache

Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Purpose: In this study, the investigators compared the effectiveness of peripheral nerve block (greater occipital nerve block with supratrochlear nerve block) versus topiramate as detoxification therapies in chronic migraine patients with medication overuse headache. Methods: At least ninety chronic migraine patients with medication overuse headache are aimed to include in this study. Patients will be divided into the two groups. The first group will receive topiramate (n=45, estimated) and the second group will receive nerve block (n=45, estimated) as detoxification therapy. Patients' records regarding the visual analog scale (VAS) scores and headache frequencies are aimed to be collected before and after the therapy. Comparisons regarding VAS scores, headache frequencies, 50% responder rates and 75% responder rates will be performed in between topiramate and nerve block groups.